Lapatinib

• Description :

  Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

• Product Name Alternative :

  GW572016; GW2016

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; EGFR; Ferroptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Lapatinib.html

• Purity :

  99.83

• Solubility :

  DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=S(CCNCC1=CC=C(C2=CC=C3C(C(NC4=CC(Cl)=C(C=C4)OCC5=CC(F)=CC=C5)=NC=N3)=C2)O1)(C)=O

• Molecular Formula :

  C29H26ClFN4O4S

• Molecular Weight :

  581.06

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1 (2) :85-94

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  EGFR/ErbB1/HER1; ErbB2/HER2

• Citation 01 :

  ACS Chem Biol. 2016 Apr 15;11 (4) :992-1000.|ACS Omega. 2022 Mar 3;7 (10) :9004-9014.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Adv Sci (Weinh) . 2023 Feb;10 (5) :e2203884.|Adv Sci (Weinh) . 2024 Nov 20:e2407662.|Analyst. 2017 Jan 26;142 (3) :525-536. |Biochim Biophys Acta Mol Basis Dis. 2024 Aug 9:167458.|Biol Proced Online. 2023 Jun 27;25 (1) :19.|Biomedical Engineering Advances. June 2022, 100040.|bioRxiv. 2019 Sep.|bioRxiv. 2021 Jan 9.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|bioRxiv. 2025 May 09.|bioRxiv. 2025 Nov 18.|bioRxiv. 2025 Sep 21.|Biotechnol Bioeng. 2021 Dec;118 (12) :4687-4698.|Br J Cancer. 2022 Mar;126 (5) :778-790.|Cancer Cell. 2025 Jul 25:S1535-6108 (25) 00310-1.|Cancer Chemother Pharmacol. 2018 Sep;82 (3) :383-394.|Cancer Lett. 2020 Apr 10;475:53-64.|Cancer Lett. 2021 Apr 28;504:125-136.|Cancer Lett. 2021 Oct 10:518:82-93.|Cancer Lett. 2024 Jun 5:217008.|Cancer Med. 2025 Sep;14 (18) :e71227.|Cancers (Basel) . 2022 Nov 28;14 (23) :5854.|Cancers (Basel) . 2024 Apr 25;16 (9) :1651.|Carcinogenesis. 2022 Dec 25;43 (11) :1071-1082.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Death Discov. 2024 Nov 1;10 (1) :462.|Cell Mol Life Sci. 2023 Mar 18;80 (4) :100.|Cell Physiol Biochem. 2015;37 (6) :2275-87.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2025 Mar 25;44 (4) :115466.|Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Clin Chim Acta. 2018 Oct:485:298-304.|Clin Transl Med. 2020 Aug;10 (4) :e148.|Commun Biol. 2024 Dec 31;7 (1) :1719.|Drug Des Devel Ther. 2020 Feb 25;14:783-793.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Eur J Med Chem. 2019 Aug 15:176:393-409.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Front Immunol. 2023 Mar 17:14:1153423.|Front Oncol. 2021 Mar 26:11:608201.|Front Pharmacol. 2021 Mar 8;12:644342.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Gene. 2022 Mar 30:816:146171.|Head Neck. 2023 Jul;45 (7) :1801-1811.|Int J Biol Sci. 2025 Jun 12;21 (9) :4081-4097.|iScience. 2023 Oct 6;26 (11) :108152.|J Biol Chem. 2022 Sep;298 (9) :102310.|J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Apr 1:1049-1050:30-40.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100.|J Exp Clin Cancer Res. 2018 Jun 25;37 (1) :123.|J Exp Clin Cancer Res. 2024 Nov 20;43 (1) :308.|J Nanopart Res. 2022; 24:261|J Proteome Res. 2022 Apr 1;21 (4) :953-964.|Life Sci. 2021 May 15:273:119239.|Mol Cancer Ther. 2018 Mar;17 (3) :603-613.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.|Nat Chem Biol. 2025 Aug;21 (8) :1226-1237.|Nat Commun. 2023 Apr 13;14 (1) :2110.|Nat Commun. 2023 Jun 15;14 (1) :3560.|Nat Immunol. 2018 Mar;19 (3) :233-245.|Nat Med. 2016 Jul;22 (7) :723-6.|Nature. 2017 Aug 24;548 (7668) :471-475. |Oncogene. 2016 Jun 9;35 (23) :2961-70. |Oncogene. 2022 May;41 (22) :3064-3078.|Oncotarget. 2017 Aug 24;8 (62) :104894-104912.|Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Open Life Sci. 2023 Jan 10;18 (1) :20220535.|Patent. US20200108066A1|Patent. US20220305013A1.|Patent. US20240293405A1.|Personalized Medicine Universe. 2019 May. |Pharmacol Res. 2025 Nov:221:107993.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|PLoS One. 2019 Apr 4;14 (4) :e0214598.|Redox Biol. 2024 Nov 5:78:103419.|RSC Adv. 2019 Jun 20;9 (34) :19325-19332.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Separations. 2023 May 26, 10 (6), 330.|SSRN. 2025 Oct 13.|Stem Cell Reports. 2017 Dec 12;9 (6) :1948-1960.|Transl Oncol. 2022 Jul; 21: 101444.|Tumour Biol. 2016 Nov;37 (11) :14831-14839.|University of Gothenburg. 2023 Jun 27.|Harvard Medical School LINCS LIBRARY|SSRN. 2025 Sep 25.

• CAS Number :

  [231277-92-2]